Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from BIO-key International ( (BKYI) ) is now available.
On April 16, 2026, BIO-key International, Inc. received notice from Nasdaq that it was not in compliance with Listing Rule 5250(c)(1) because it failed to timely file its Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission. The notification does not immediately affect the listing or trading of BIO-key’s common stock on the Nasdaq Capital Market, but it flags a regulatory deficiency that investors typically monitor closely.
The company said on April 22, 2026, that it is working with its auditors to finalize the delayed annual report and expects to submit the Form 10-K in the following week. While the immediate trading status remains unchanged, timely resolution of the filing delay will be important for maintaining Nasdaq compliance and reassuring shareholders about the company’s reporting reliability and governance practices.
The most recent analyst rating on (BKYI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on BIO-key International stock, see the BKYI Stock Forecast page.
Spark’s Take on BKYI Stock
According to Spark, TipRanks’ AI Analyst, BKYI is a Neutral.
The score is held down primarily by weak financial performance (persistent large losses and negative cash flow) and bearish technical positioning (price below key moving averages with negative MACD). The earnings call provides some offset via improved near-term revenue guidance and operational progress, but the negative P/E and lack of dividend yield reinforce that the investment case depends on executing a turnaround.
To see Spark’s full report on BKYI stock, click here.
More about BIO-key International
BIO-key International, Inc. is a global provider of identity and access management and biometric authentication technologies, offering biometric-centric, multi-factor IAM software that secures access for more than forty million users. Its cloud-hosted and on-premise PortalGuard IAM platform enables phoneless, tokenless, and passwordless authentication, targeting organizations that require cost-effective, secure access to computers, applications, data, and high-value transactions.
The company focuses on delivering convenient and robust cybersecurity solutions for diverse use cases, allowing customers to tailor authentication factors to their security and usability needs. By emphasizing biometric options and flexible deployment models, BIO-key positions itself within the cybersecurity and IAM market as a specialized vendor aiming to simplify secure access management for enterprises and institutions.
Average Trading Volume: 3,311,146
Technical Sentiment Signal: Sell
Current Market Cap: $6.82M
For a thorough assessment of BKYI stock, go to TipRanks’ Stock Analysis page.